BOSTON — In a phase 2b trial, a hormonal contraceptive gel for use by men worked faster than expected, suppressing sperm count to effective levels by week 8 of use, making it an “attractive” product, according to a speaker at ENDO 2024.
The gel combines the progestin segesterone acetate (Nestorone) with testosterone to suppress endogenous testosterone production and replace just enough testosterone to reach physiologic levels to maintain normal functions that depend on androgens, according to senior researcher Diana Blithe, PhD, chief of the Contraceptive Development Program